Evaluation the Efficacy and Safety of Tocilizumab in COVID-19

Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151227025726N13

Enrollment

Registered

2020-03-26

Start date

2020-03-11

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. Confirmed diagnosis of COVID-19

Interventions

Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Laboratory confirmed COVID-19 with RT-PCR Respiratory rate > 30/min Oxygen saturation < 90% PaO2/FiO2 < 300mmHg High level of serum Interleukin-6 Age over 18 years old

Exclusion criteria

Exclusion criteria: Chronic kidney Disease Acute kidney injury Pregnancy or breastfeeding Drug allergy history Pneumonia due to influenza virus, bacterial pneumonia, fungal pneumonia, and noninfectious causes Chronic liver disease History of latent or active tuberculosis Patients with human immunodeficiency virus

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.	—

Secondary

Measure	Time frame
Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.	—

Measure

Time frame

Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse Drug Reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Dastan

Shahid Beheshti University of Medical Sciences

f_dastan@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026